SCM
TEVA icon

Suvretta Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Suvretta Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-575,000
Closed -$35.8M – 38
2015
Q1 		$35.8M Buy
+575,000
New +$33.4M 2.14% 20

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Suvretta Capital Management's TEVA Position: Q4 2024 in Review

Suvretta Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 268,100 shares — an estimated $4.83M sold.

Suvretta Capital Management first reported a position in TEVA in Q1 2014 and held it in 8 quarters. The position peaked at $93.7M in Q4 2015. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Suvretta Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 268,100 Teva Pharmaceuticals shares in Q4 2024, an estimated $4.83M.
  • Suvretta Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 8 quarters.
  • Suvretta Capital Management's Teva Pharmaceuticals position peaked at $93.7M in Q4 2015.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.